These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38729563)

  • 1. Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review.
    Mirza M; Goerke L; Anderson A; Wilsdon T
    Value Health; 2024 May; ():. PubMed ID: 38729563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
    Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
    J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
    Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A
    Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.
    Pipitprapat W; Pattanaprateep O; Iemwimangsa N; Sensorn I; Panthan B; Jiaranai P; Chantratita W; Sorapipatcharoen K; Poomthavorn P; Mahachoklertwattana P; Sura T; Tunteeratum A; Srichan K; Sriphrapradang C
    Ann Med; 2021 Dec; 53(1):1243-1255. PubMed ID: 34309460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
    Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluations of Next-Generation Precision Oncology: A Critical Review.
    Weymann D; Pataky R; Regier DA
    JCO Precis Oncol; 2018 Nov; 2():1-23. PubMed ID: 35135140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access and quality of biomarker testing for precision oncology in Europe.
    Normanno N; Apostolidis K; Wolf A; Al Dieri R; Deans Z; Fairley J; Maas J; Martinez A; Moch H; Nielsen S; Pilz T; Rouleau E; Patton S; Williams V
    Eur J Cancer; 2022 Nov; 176():70-77. PubMed ID: 36194905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness.
    Tan O; Shrestha R; Cunich M; Schofield DJ
    Clin Genet; 2018 Mar; 93(3):533-544. PubMed ID: 29265354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.
    Joosten SEP; Retèl VP; Coupé VMH; van den Heuvel MM; van Harten WH
    BMC Cancer; 2016 Feb; 16():66. PubMed ID: 26851938
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.